Status:
TERMINATED
The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab
Lead Sponsor:
Kobe City General Hospital
Conditions:
Advanced Non-small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
For patients with nonsquamous NSCLC and a good performance status (PS), pemetrexed and cisplatin has been recommended for first-line NSCLC treatment. Recently, results from the PARAMOUNT trial showed ...
Eligibility Criteria
Inclusion
- 20 Years and older
- PS0-2
- Advanced non-squamous non-small cell lung cancer; AND
- Patients who have received more than 4 cycles of pemetrexed therapy before the study
Exclusion
- Interstitial pneumonia; AND
- Abnormal blood test
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02200354
Start Date
July 1 2014
End Date
March 20 2019
Last Update
August 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan, 650-0046